Pharmacokinetic modelling and validation of the half-life extension needed to reduce the burden of infusions compared with standard factor VIII.

Cedric Hermans Johnny N Mahlangu J Booth Helmut SchützE SantagostinoGuy Aaron YoungH-Y LeeK N Steinitz-TrostV BlanchetteE Berntorp

Published in: Haemophilia : the official journal of the World Federation of Hemophilia (2018)

Based on this investigation, EHL rFVIII products should have a minimum half-life extension ratio of 1.3 to provide a reduction in dosing frequency from 3× to 2×/wk compared with standard rFVIII products while maintaining the same minimum FVIII trough level.

Keyphrases